Profile data is unavailable for this security.
About the company
Bio-Path Holdings, Inc. is a biotechnology company. The Company is engaged in developing DNAbilize, a novel technology that has yielded a pipeline of RNAi nanoparticle drugs that can be administered with a simple intravenous transfusion. DNAbilize, is a platform that uses P-ethoxy, which is a deoxyribonucleic acid (DNA) backbone modification that is intended to protect the DNA from destruction by the body’s enzymes when circulating in vivo, incorporated inside of a lipid bilayer having neutral charge. Its lead product candidate, prexigebersen (BP1001, targeting the Grb2 protein), is in a Phase II study for blood cancers, and BP1001-A, a drug product modification of prexigebersen, is in a Phase I/Ib study for solid tumors. The Company’s second product, BP1002, which targets the Bcl-2 protein, is being evaluated for the treatment of blood cancers and solid tumors, including lymphoma and acute myeloid leukemia. BP1003 is its third liposome delivered antisense drug candidate.
- Revenue in USD (TTM)0.00
- Net income in USD-16.08m
- Incorporated2014
- Employees10.00
- LocationBio Path Holdings Inc4710 BELLAIRE BOULEVARD, SUITE 210BELLAIRE 77401United StatesUSA
- Phone+1 (832) 742-1357
- Fax+1 (916) 443-1908
- Websitehttps://www.biopathholdings.com/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Bon Natural Life Ltd | 29.52m | 4.60m | 3.87m | 96.00 | 0.5571 | 0.092 | 0.7036 | 0.1313 | 4.99 | 4.99 | 32.10 | 30.23 | 0.7045 | 15.27 | 5.19 | 307,524.60 | 10.86 | 14.04 | 13.69 | 20.68 | 29.94 | 30.00 | 15.42 | 17.62 | 2.41 | 30.54 | 0.0955 | 0.00 | -1.29 | 22.32 | -26.32 | 83.09 | -6.70 | -- |
| Evoke Pharma Inc | 5.18m | -7.79m | 3.98m | 4.00 | -- | -- | -- | 0.7691 | -2.33 | -2.33 | 1.55 | -0.7716 | 0.5476 | 0.5235 | 7.98 | 1,295,158.00 | -82.37 | -100.48 | -109.52 | -151.10 | 96.10 | -- | -150.41 | -480.52 | 2.09 | -20.56 | 2.07 | -- | 106.51 | -- | 5.25 | -- | -- | -- |
| Aptevo Therapeutics Inc | 0.00 | -18.65m | 3.99m | 40.00 | -- | 0.0402 | -- | -- | -77.09 | -70.57 | 0.00 | 27.62 | 0.00 | -- | -- | 0.00 | -63.16 | -47.16 | -86.49 | -85.03 | -- | -- | -- | -583.47 | -- | -- | 0.00 | -- | -100.00 | -- | -365.90 | -- | -- | -- |
| Phio Pharmaceuticals Corp | 0.00 | -10.83m | 4.04m | 8.00 | -- | 0.4263 | -- | -- | -6.40 | -6.40 | 0.00 | 2.06 | 0.00 | -- | -- | 0.00 | -97.63 | -71.92 | -116.38 | -84.15 | -- | -- | -- | -253,785.70 | -- | -- | 0.00 | -- | -- | -- | 5.70 | -- | 0.00 | -- |
| TRACON Pharmaceuticals Inc | 12.05m | -3.59m | 4.12m | 17.00 | -- | -- | -- | 0.3419 | -5.20 | -5.20 | 7.36 | -0.3655 | 0.8146 | -- | -- | 708,529.40 | -24.26 | -79.42 | -- | -177.85 | -- | -- | -29.79 | -813.81 | -- | -0.9444 | -- | -- | -- | 32.05 | 87.68 | -- | -- | -- |
| Sentient Brands Holdings Inc | 160.00 | -379.70k | 4.18m | 2.00 | -- | -- | -- | 26,150.52 | -0.007 | -0.007 | 0.00 | -0.0308 | 0.0006 | -0.0026 | -- | 80.00 | -149.74 | -224.47 | -- | -- | 462.50 | 41.35 | -237,312.50 | -27,393.23 | 0.0005 | -0.6995 | -- | -- | -16.18 | -- | -100.19 | -- | -- | -- |
| Bio Path Holdings Inc | 0.00 | -16.08m | 4.24m | 10.00 | -- | 3.80 | -- | -- | -35.76 | -35.76 | 0.00 | 0.7136 | 0.00 | -- | -- | 0.00 | -167.56 | -70.80 | -206.12 | -76.87 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -15.94 | -- | -- | -- |
| Artelo Biosciences Inc | 0.00 | -9.29m | 4.26m | 6.00 | -- | 0.3582 | -- | -- | -3.12 | -3.12 | 0.00 | 3.69 | 0.00 | -- | -- | 0.00 | -55.51 | -- | -59.59 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | 7.87 | -- | -- | -- |
| Reliv International Inc | 35.13m | -175.48k | 4.30m | 208.00 | -- | 0.6201 | 10.75 | 0.1223 | -0.1005 | -0.1005 | 20.12 | 6.55 | 2.09 | 8.02 | 228.49 | -- | -1.05 | -4.65 | -1.47 | -6.06 | 40.90 | 41.98 | -0.4996 | -2.33 | 1.07 | -- | 0.1064 | -- | -2.94 | -9.37 | 76.65 | -- | -35.85 | -- |
| Exicure Inc | 23.79m | 3.07m | 4.30m | 7.00 | 0.3888 | 0.4429 | 1.04 | 0.1807 | 1.28 | 1.28 | 3.86 | 1.12 | 0.8729 | -- | -- | 1,830,000.00 | 11.25 | -41.75 | 18.34 | -55.57 | -- | -- | 12.88 | -302.07 | -- | -- | 0.00 | -- | 6,068.12 | 24.29 | 95.97 | -- | -59.57 | -- |
| Theralink Technologies Inc | 635.46k | -13.50m | 4.31m | 16.00 | -- | -- | -- | 6.78 | -0.0027 | -0.0027 | 0.00006 | -0.0093 | 0.2525 | -- | 13.51 | 39,716.25 | -536.39 | -- | -- | -- | 73.50 | -- | -2,124.10 | -- | -- | -1.35 | -- | -- | 6.85 | -- | -138.38 | -- | -- | -- |
| Tharimmune Inc | 0.00 | -9.32m | 4.34m | 2.00 | -- | 0.4731 | -- | -- | -13.09 | -13.09 | 0.00 | 0.7778 | 0.00 | -- | -- | 0.00 | -105.69 | -- | -127.01 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -9.98 | -- | -- | -- |
| Mosaic Immunoengineering Inc | 0.00 | -1.01m | 4.35m | 3.00 | -- | -- | -- | -- | -0.1397 | -0.1397 | 0.00 | -0.8107 | 0.00 | -- | -- | 0.00 | -457.45 | -- | -- | -- | -- | -- | -- | -- | -- | -35.84 | -- | -- | -- | -- | 57.65 | -- | -- | -- |
| AccuStem Sciences Inc | 0.00 | -2.05m | 4.40m | 3.00 | -- | -- | -- | -- | -0.1807 | -0.1807 | 0.00 | -0.1861 | 0.00 | -- | -- | 0.00 | -382.02 | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | 45.26 | -- | -- | -- |
| GT Biopharma Inc | 0.00 | -7.60m | 4.45m | 2.00 | -- | 0.5947 | -- | -- | -5.57 | -5.57 | 0.00 | 5.41 | 0.00 | -- | -- | 0.00 | -49.26 | -205.36 | -78.83 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | 63.62 | -- | -- | -- |
| Manuka Inc | 671.00k | -1.14m | 4.48m | 4.00 | -- | -- | -- | 6.68 | -0.0128 | -0.0128 | 0.0066 | -0.0124 | 2.41 | 0.9412 | 37.28 | 167,750.00 | -410.43 | -463.75 | -- | -- | 88.08 | -- | -170.04 | -732.15 | 0.0194 | -- | -- | -- | -- | -- | -854.23 | -- | -- | -- |
Data as of May 07 2024. Currency figures normalised to Bio Path Holdings Inc's reporting currency: US Dollar USD
36.84%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| The Vanguard Group, Inc.as of 31 Dec 2023 | 135.02k | 17.91% |
| Geode Capital Management LLCas of 31 Dec 2023 | 55.22k | 7.33% |
| BlackRock Fund Advisorsas of 31 Dec 2023 | 27.36k | 3.63% |
| Citadel Securities LLCas of 31 Dec 2023 | 12.10k | 1.61% |
| UBS Securities LLCas of 31 Dec 2023 | 11.39k | 1.51% |
| Northern Trust Investments, Inc.(Investment Management)as of 31 Dec 2023 | 8.86k | 1.18% |
| HRT Financial LLCas of 31 Dec 2023 | 8.65k | 1.15% |
| XTX Markets LLCas of 31 Dec 2023 | 7.70k | 1.02% |
| SSgA Funds Management, Inc.as of 31 Dec 2023 | 6.52k | 0.87% |
| Tower Research Capital LLCas of 31 Dec 2023 | 4.86k | 0.65% |
More ▼
Data from 31 Dec 2023 - 31 Dec 2023Source: FactSet Research Systems Inc.
